Work

Liraglutide ameliorates inflammation and fibrosis by downregulating the TLR4/MyD88/NF-κB pathway in diabetic kidney disease

Year: 2024

Type: article

Abstract: Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has renoprotective effect in diabetic kidney disease (DKD). In DKD, TLR4/MYD88/NF-κB signaling is involved in the regulation of inflammatory responses and extracellular matrix (ECM) protein proliferation. Liraglutide attenuates renal inflammation and overexpression of ECM proteins by inhibiting TLR4/MYD88/NF-κB signaling pathway. Therefore, we have identified a new mechanism that contributes to the renal protection of GLP-1RA, thus helping to design innovative treatment strategies for diabetic patients with various complications.

Source: American Journal of Physiology-Regulatory, Integrative and Comparative Physiology

DOI: 10.1152/ajpregu.00083.2024

Authors: Linjing Huang, Tingting Lin, Meizhen Shi, Peiwen Wu

Institutions: Fujian Medical University, First Affiliated Hospital of Fujian Medical University

Language: English

Topic: Chronic Kidney Disease and Diabetes

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funders: Science and Technology Projects of Fujian Province, Fujian Provincial Health Commission, Fujian Provincial Health Technology Project